When blisters form on an injured area, although sometimes periodically with a non-scented, non-greasy moisturizer [4]. In addition, the wound is left uncovered and moisturized process as soon as possible, followed by applying cool running damaged. The skin will turn white and lose sensation [2].

Third-degree burn suffers an even deeper damage involving all layers of skin; moreover, the nerves and blood vessels are also additional pain sensation and blister formation on the skin. A degree burn. It is usually characterized by mild pain, redness and that affects the epidermal layer of skin is classified as a first-degrees of burn are classified. A superficial burn such as sunburn wound. Depending on the depth of skin being affected, different leading cause of scalds [1].

First-aid treatment for scalds involves stopping the burning process as soon as possible, followed by applying cool running water to cool down the skin to help reduce damage immediately [3]. In addition, the wound is left uncovered and moisturized periodically with a non-scented, non-greasy moisturizer [4]. When blisters form on an injured area, although sometimes deroofing a blister is necessary, it is recommended not to burst a blister as it may increase chances of infection. For small blisters with pale pink or mottled appearance, they may take 3-8 weeks to heal without or with minimal scarring. However, regarding deep dermal scald injuries forming large botchy cherry red blisters, it may take over 8 weeks or a prolonged time to heal with potential scarring [5], and may require surgical treatments for functional recovery [5].

Our laboratory has been involved in the development of microbial systems for cost-effective production of useful or valuable recombinant proteins [6-14]. Among the target proteins, we have been interested in skin growth proteins, including human epidermal growth factor (EGF) and human basic fibroblast growth factor (bFGF), which are key members among skin growth proteins in providing maintenance and regeneration to the epidermal and dermal layers, respectively, of our skin.

Both EGF and bFGF have been discovered over 30 to 40 year [15-17]. During this long period of time, both factors have been studied extensively and shown that they are involved in a wide range of biological functions [15,17-24], supporting that they are potentially applicable for use as therapeutics for treating various physiological disorders. However, both EGF and bFGF cost hundreds of thousands of USD for just one gram of product, despite the fact that both factors have been shown to be highly active in promoting wound healing [18,20,23,24] and growth of various cell types [25,26]. The high prices of EGF and bFGF restrict their research for clinical applications to certain wound types and small-scale studies.

Employing efficient bacterial systems developed in our laboratory, we have been successful in cost-effective production of recombinant EGF and bFGF possessing authentic primary structures [8,9,11]. Results from recent studies have offered support to the view that sequence authenticity is not only
important for recombinant EGF and bFGF to maintain their structural stability [8,9,11], but is also crucial for both factors to acquire potent bioactivities [8,9,22,24]. Previously we have made use of cream base supplemented with 0.04% (w/w) of our recombinant EGF (rEGF) to successfully treat sporadic cases of scald injury, with an example shown in Figure 1. However, the healing process of these injuries was not well monitored. In this communication, we report, with careful monitoring of the progress of recovery, the use of rEGF for effective treatment of three incidents of scald injury, even in cases where blisters had burst and red patches of skin had emerged.

**Materials and Methods**

**Source of recombinant EGF**

Expression of recombinant EGF (rEGF) was achieved using Escherichia coli JM101 [pWKW2] transformant [11-13], in which the conditions for induced production of rEGF were described previously [8,11-14]. Details for purification of rEGF, characterization of the authentic structure of rEGF, and confirmation of rEGF being devoid of either toxic or allergenic property have been reported previously [8,11].

**Preparation of treatment cream containing rEGF**

The cream base, named Watsons Aqueous Cream [27] was purchased from Watsons Hong Kong. To prepare the treatment cream containing rEGF, purified rEGF dissolved in sterile ddH2O was added into the cream base to a final concentration of 0.04% (w/w). The content was then mixed thoroughly until rEGF was evenly distributed to form the final product, designated “Enhanced Cream” (EC), with rEGF supplemented to a final concentration of 0.04% (w/w).

**Treatment of scalds with EC**

In treating a burst or broken blister resulting from a previously scalded wound, the affected area was first cleansed thoroughly with diluted dettol [23] as recommended by the manufacturer. The disinfected area was then topically applied with a slight film of EC, followed by covering with a gauze pad as described previously [23]. The application was done twice a day.

With respect to a fresh scald injury caused by hot water, EC was applied swiftly to the affected area. If the scald results from hot fluids other than water, it is advisable that the affected area is first rinsed with cool water, then dried with a clean tissue or soft towel, followed by applying EC to the affected area.

**Results and Discussion**

**Treatments of previously scalded wounds**

Treatments of three female victims of different ages suffering scald injuries in different parts of the body caused by hot water were reported. In all three cases, the scalds failed to receive immediate medical care, thus leading to the formation burst blisters, and subsequently to the appearance of red to cherry red patches on skin.

**Case 1:** A 1-year-old toddler girl suffered second-degree scalding burns on her submental region (Figure 2) in Guangzhou, China. Soon after the accident, a large painful blister was developed on the girl’s scalded chin. She was attended by a medical doctor in a clinic and was prescribed a cream supplemented with a locally produced skin growth factor (personal communication with the girl’s father) for topical application onto the wound. Despite being treated with the cream and visiting the clinic twice, the girl still groaned in pain and the blister subsequently burst; there was no sign of improvement (Figure 2). The parents were even warned that despite recovery, the scalding injury might still leave a scar on the girl’s chin.
The girl’s parents were then referred to us by a friend who knows our accomplishments in treating ulcers and other wounds with recombinant human epidermal growth factor (rEGF) [22-24]. Immediately, we prepared “Enhanced Cream” (EC), which contained 0.04% (w/w) rEGF (Materials and methods), for treating the girl’s scald injury, which began on the 4th day after the accident.

On the 1st to 5th day of the treatment, the wound showed peeling of remnants of the burst blister (Figure 2). In addition, there appeared healing signs as reflected by: signification pain reduction in the girl’s wound, smoothening of the boundaries of the original scald, and discoloration of the pinkish red patch on the skin. In the next nine days, the wound healed readily and complete healing appeared to occur in two weeks without scarring (Figure 2).

**Case 2:** Concurrently, similar to the first case, a 7-year-old girl residing in Hong Kong also suffered second-degree scalding injuries; but this time, the affected region concentrated essentially on the left thigh (Figure 3). Blisters formed swiftly on the scaled skin and subsequently burst. The girl was sent to see a clinician on the next day after the accident and Silviro Sulf Cream [28] was prescribed for treating the scalds. Soon after the treatment, the girl’s father reckoned that the cream might not have a significantly positive effect on healing the wounds; he then approached us and procured EC to treat his daughter’s injuries. EC was applied to the wounds as mentioned in Materials and methods. The medical doctor initially predicted that it would take at least two weeks for the wounds to heal. However, after 12 days of EC treatment, it was quite surprising to observe that the wounds showed apparently complete healing (Figure 3). Subsequently, on the 14th day of EC treatment, the wounds archived complete healing without scar formation.

**Case 3:** In the third case, a 30-year-old female Hong Kong citizen suffered scald injuries resulting from steam generator bought from China while she was employing the machine to facilitate foot massage treatment. However, while the massage was in process, the machine suddenly exploded. Since it was quite an explosion, the lady was much more seriously scalded than the two patients referenced in the first and second cases. Certain parts of the scalds were considered as severe second-degree to even third-degree burns (Figure 4). She was admitted to St. Teresa’s Hospital and was subscribed a 2.5% sodium hyaluronate based wound dressing [29] for the management of the wounds. Despite treatment with the dressing for 11 days, there was only little improvement in the healing of the wounds. The patient then switched to the use of EC to replace the dressing to provide continuous treatment of the scalds. Despite delayed treatment with EC, the progress of healing of the wounds was phenomenal. With only one day of treatment,
discoloration of the reddish patches and regeneration of new skin were significantly noted (Figure 4). After six days of treatment, the wounds were apparently healed without any signs of formation of the previously concerned side effect – scarring (Figure 4).

Figure 3: Treatment of scalding injuries on the thigh region of a 7-year-old girl with EC supplemented with 0.04% (w/w) rEGF. The duration in day(s) of the treatment is shown on top of the picture.

Figure 4: Treatment of scalding injuries on the two legs of a 30-year-old woman with EC supplemented with 0.04% (w/w) rEGF. The duration in day(s) of the treatment is shown on top of the picture. Before treatment stands for before treating with EC.
Treatment of freshly scalded skin

An effective way of treating freshly scalded injuries caused commonly by spilled hot liquids, e.g. water, may have to avoid subsequent complications including formation of blisters, potential scarring [5,30] and requirement of surgical treatments for functional recovery [5]. In an accident, a 30-year-old male got scalded by boiling water spilled on his right forearm (Figure 5A). The scald was immediately treated with EC, of which an excessive amount was applied to fully cover the wound. The cream was then left uncovered and the application lasted for at least one hour. Upon application, EC provided the patient with instant relief from pain. Moreover, after one hour of EC application, there was no sign of blister formation or change of color of the skin where the scald wound was initially noted (Figure 5A). Even without further treatment with EC, the forearm appeared to be normal and showed no scalding sign (Figure 5A).

Notwithstanding the effective performance of EC in protecting the scalded skin from further development of harmful side effects including blister formation (Figure 5A), an appropriate administration of EC to a scald wound appeared to be crucial to effective application of EC. For example, the duration of EC application to a scald injury was too short, as it was observed in treating the hot water spill on the 62-year-old male’s forearm (Figure 5B). Although EC was applied to the wound right after the accident, in only 15 min or so, the treated area was covered with a bandage until the next morning. This format of EC application appeared to be still effective in reducing pain (personal communication). However, quite unexpectedly, despite the treatment, a fluid-filled blister formed on the scalded skin (Figure 5B).

![Figure 5: Healing progress of freshly scalded skin with (A) 60 minutes or (B) 15 minutes of EC application. Before treatment stands for before treating with EC.](image)

Discussion

There have been a number of articles reporting the beneficial effect of EGF in healing of scald wounds in both animal and human subjects [31-34]. Notwithstanding the supporting data shown by these reports, EGF has still been scarcely employed as remedy for treating scald or burn injuries. The concerns about safety, high prices and inconsistent qualities of EGF have presented as major obstacles to the widespread application of EGF to the treatment of burn and scald wounds. These difficulties have been related to cost-effective production of quality EGF for commercial applications.
Our laboratory has endeavored to develop efficient microbial systems for large-scale production of recombinant EGF (rEGF) \[8,11-14,22-24\]. The resulting rEGF is not only available at a much lower price, which is about 10-15% of that of its commercial counterparts \[35\], but is also verified to possess an authentic structure of 53 amino acids and free from toxic and allergenic activities \[11\].

Using rEGF produced by our group and other teams \[10,13,36\], we have demonstrated that rEGF is effective in treating a number of skin wounds including diabetic foot ulcers \[24\], Stevens-Johnson syndrome \[22\] and surgical wounds \[23\]. Despite the well-defined efficacies of rEGF revealed in treating various wounds and other healthcare applications \[22-24\], rEGF available from other sources might not be able to yield the same or reproducible results as ours, thus creating confusion and uncertainty regarding the exact effectiveness of rEGF in applications. In many of these studies, however, the chemical structure and quality of rEGF employed have not been discretely specified. It has been shown that skin growth factors possessing unauthentic structures are either highly susceptible to degradation or biologically less active \[37\]. Thus, using EGF with compositions different from that of native EGF in experimental work could seriously affect the overall research outcome. In this regard, there have been reports claiming that EGF was ineffective in treating scald or burn injuries \[33\]. These controversial results, unfortunately, would reduce our confidence in further development of rEGF for drug applications, which have been shown to be potentially broad \[22-24,33,34\].

In view that unexpected patients receiving immediate medical treatments were the best witnesses regarding whether nEGF was effective in treating scald wounds, EC was freshly prepared and employed to treat patients suffering previously or freshly scald injuries caused by hot water spillage. It was apparent that continuous application of the commercial products, e.g. Silvirsulf Cream (see Case 2 in Results;\[28\]) would not result in more beneficial outcomes in the three cases of previously scalded wounds. Further delay in treating the wounds with effective medications could lead to complications including infections and scar formation after healing. Obviously, with application of EC to the wounds, the healing process was effectively speeded up. In all three cases, the processes of shedding dead skin and regeneration of new skin were enhanced (Figure 2-4). Last but not least, the wounds healed well without scar formation (Figure 2-4).

We were surprised to note that prolonged application of EC to a freshly scalded wound was effective in not only alleviating pain, but also preventing blister formation (Figure 5A). It has been postulated that blister formation begins with epidermal cells in the prickle-cell layer that have lost their structural connections. This area of separation of cells will then be filled with fluid within 2 h to form a blister \[38\]. Although the exact mechanism of how EC functions to prevent blister formation, presumably it works to maintain integrity of the epidermis, in particular the prickle-cell layer, thus avoiding subsequent influx of fluid to form the vesicle, in not known. In order to keep the cell layers intact, it might be necessary for rEGF to be kept on the scalded skin for a long enough time to exert its function. The interpretation might help to explain why the scalded wound, which was covered with a bandage soon after EC was added for only 15min, on the 62-year-old victim resulted in the formation of a blister (Figure 5B). Therefore, the presence of the bandage might, on the one hand, "take away" by absorbing some of the applied EC, and on the other hand, affect oxygen supply, which might be required by rEGF for functional activity. This postulation gains support from previous findings that sufficient transport of oxygen and nutrients to injured tissues is important to allow scalded areas to achieve better skin regeneration and recovery \[39\].

Regardless the exact mechanism of how rEGF facilitates healing of scald wounds, our results suggest that rEGF may serve as an effective first-aid treatment for a scald or burn injury, which may further be developed to harmful side effects in duding blister formation, infections and scarring upon healing if the wound was not effectively treated initially. Since we have employed a high concentration, 0.04% (w/w), of rEGF in all the treatments discussed, it may be economically worthwhile to see whether there exists a dose-response relationship between rEGF concentration and effective treatment of different severities of scald or burn injuries.

**Conclusion**

Authentic rEGF containing 53 amino acid residues is effective in treating scald injuries. Aqueous cream containing 0.04% (w/w) rEGF (EC) was shown to be able to promote regeneration and restoration of second-degree scald wounds, previously or freshly incurred. On previously scalded skin, EC helped to exfoliate dead skin, promote epidermal cell growth, and prevent scar formation. While on freshly scalded skin, prolonged EC treatment could prevent blister formation and development of other complications.

**Acknowledgement**

This study was funded by RGC project: GRF16101515 and Research Contract: 13142580CLIL07W011 awarded to W.K.R. Wong.

**References**

1. Turner C, Spinks A, McClure R, Nixon J (2004) Community-based interventions for the prevention of burns and scalds in children. Cochrane Database Syst Rev (3): CD004335.
2. Pulia N, von Bülow S (2006) Behandlungskonzepte bei Verbrennungen. Der Chirurg 77(1): 81-94.
3. Hudspith J, Rayatt S (2004) First aid and treatment of minor burns. BMJ 328(7454): 1467-1469.
4. http://www.wisegeek.com/what-is-a-scald.htm
5. http://patient.info/in/doctor/burns-assessment-and-management
6. Wong WKR (2008) Application of recombinant microbial systems to the production of commercially valuable proteins. Research Journal of Biotechnology 3(3): 3-4.
7. Wong WKR, Lam E, Huang RC, Wong RS, Morris C, et al. (2001) Applications, and efficient large-scale production, of recombinant human epidermal growth factor. Biotechnol Genet Eng Rev 18: 51-71.
8. Kwong KYW, Wong WKR (2013) A revolutionary approach facilitating co-expression of authentic human epidermal growth factor and basic fibroblast growth factor in both cytoplasm and culture medium of Escherichia coli. Appl Microbiol Biotechnol 97(10): 9071-9080.
9. Kwong KWY, Ng KL, Lam CC, Wang YY, Wong WKR (2012) Authentic human basic fibroblast growth factor produced by secretion in Bacillus subtilis. Appl Microbiol Biotechnol 97(15): 6803-6811.

10. Wong WKR, Fu Z, Wang YV, Ng KL, Chan AKN (2012) Engineering of efficient Escherichia coli excretion systems for the production of heterologous proteins for commercial applications. Recent Patents on Chemical Engineering 5(1): 44-55.

11. Huang R, Lam E, Chen Y, Hackett J, Lam T, et al. (1999) Human epidermal growth factor excreted by recombinant Escherichia coli K-12 has the correct N-terminus and is fully bioactive. Process Biochemistry 35(1-2): 1-5.

12. Wong DKH, Lam KHE, Chan CKP, Wong YCV, Wong WKR, et al. (1998) Extracellular expression of human epidermal growth factor encoded by an Escherichia coli K-12 plasmid stabilized by the ytl2-incR system of Salmonella typhimurium. Journal of Industrial Microbiology and Biotechnology 21(1-2): 31-36.

13. Swakesava S, Xu Z, Chen Y, Hackett J, Huang R, et al. (1999) Production of excreted human epidermal growth factor (hEGF) by an efficient recombinant Escherichia coli system. Process Biochemistry 34(9): 893-900.

14. Kwong KWY, Ng AKL, Wong WKR (2015) Engineering versatile protein expression systems mediated by inteins in Escherichia coli. Appl Microbiol Biotechnol 100(1): 1-8.

15. Carpenter G, Cohen S (1979) Epidermal growth factor. Annu Rev Biochem 48: 193-216.

16. Cohen S (1962) Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the newborn animal. J Biol Chem 237: 1555-1562.

17. Ribatti D, Vacca A, Rusnati M, Presta M (2007) The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies. Cytokine & Growth Factor Rev 18(3-4): 327-334.

18. Hebda PA, Klingbeil CK, Abraham JA, Fiddes JC (1990) Basic Fibroblast Growth Factor StimULATION of Epidermal Wound Healing in Pigs. J Invest Dermatol 95(6): 626-632.

19. Sasaki N, Nishii S, Yamada K, Huruoka H, Tabata Y (2013) Effect of Gelatin Hydrogel Sheet Containing Basic Fibroblast Growth Factor on Proximal Sesamoid Bone Transverse Fracture Healing in the Horse. Journal of Equine Veterinary Science 33(3): 210-214.

20. Nanney LB (1990) Epidermal and Dermal Effects of Epidermal Growth Factor During Wound Repair. J Invest Dermatol 94(5): 624-629.

21. Montero RB, Vial X, Nguyen DT, Farhand S, Reardon M, et al. (2012) bFGF-containing electrospun gelatin scaffolds with controlled nano-architectural features for directed angiogenesis. Acta Biomaterialia 8(5): 1778-1791.

22. Tsang MW, Tsang KY, Wong WKR (2004) The use of recombinant human epidermal growth factor (rhEGF) in a gentleman with drug-induced Steven Johnson syndrome. Dermatol Online J 10(1): 25.

23. Wong WKR (2015) Effective Treatment of an Unhealed Incision of a Diabetic Patient with Recombinant Human Epidermal Growth Factor. Modern Chemistry & Applications 3: 166.

24. Tsang MW, Wong WKR, Chu CM, Lam EKH, Tsang MW, et al. (2003) Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care 26(6): 1856-1861.

25. Xu C, Rosler E, Jiang J, Lebkowski JS, Gold JD, et al. (2005) “Basic Fibroblast Growth Factor Supports Undifferentiated Human Embryonic Stem Cell Growth Without Conditioned Medium. Stem cells 23(3): 315-323.

26. Ryu SH, Moon SY, Yang YJ, Moon SR, Hong JP (2009) Recombinant Human Epidermal Growth Factor Accelerates the Proliferation of Irradiated Human Fibroblasts and Keratinocytes in vitro and in vivo. J Radiat Res 50(6): 545-552.

27. http://www.watsons.com.hk/Product-WATSONS/Watsons-Aqueous-Cream/p/VP_259029

28. http://www.sankinghampharma.com/

29. http://glycobiosciences.com/iptm-wound-gel-0

30. Cuttle L, Pearn J, McMillan JR, Kimble RM (2009) A review of first aid treatments for burn injuries. Burns 35(6): 768-775.

31. Gregory LB, Lillian BN, Joseph G, Anne BC, John MV, et al. (1989) Enhancement of Wound Healing by Topical Treatment with Epidermal Growth Factor. The New England Journal of Medicine 321: 76-79.

32. Liang Z, Wang S, Jieli MA, Jiale C, Minghao X (2000) Recombinant human epidermal growth factor in treatment of 100 cases of burn wounds. Chinese New Drugs Journal.

33. Thornton JW, Hess CA, Cassingham V, Bartlett RH (1982) Epidermal growth factor in the healing of second degree burns: a controlled animal study. Burns Incl Therm Inj 8(3): 156-160.

34. Almtdarajlu C, Dogim Z, Celebi N, Zor F, Öztürk S, et al. (2006) An investigation on burn wound healing in rats with chitosan gel formulation containing epidermal growth factor. Burns 32(3): 319-327.

35. http://www.biocompare.com/Search-Biomolecules/?search=huma n+epidermal+growth+factor

36. Esipov RS, Stepanenko VN, Chupova LA, Boyarskikh UA, Filipenko MA, et al. Production of recombinant human epidermal growth factor using Ssp dnaB mini-intein system. Protein Expression and Purification 61(1): 1-6.

37. Zhang M, Jiang X, Su Z, Lin J, Xiang Q, et al. Large-scale expression, purification, and glucose uptake activity of recombinant human FGF21 in Escherichia coli. Appl Microbiol Biotechnol 93(2): 613-621.

38. http://www.blisterevention.com.au/the-advanced-guide-to-blist er-division/#.V8fxhTVEDIV

39. Benson A, Dickson WA, Boyce DE (2006) Burns. BMJ 332(7542): 649-652.